Dose-limiting toxicities remain a major barrier to drug development and therapy, revealing the limited predictive power of human genetics. Here, we demonstrate the utility of a more comprehensive approach to studying drug toxicity through longitudinal profiling of the human gut microbiome during colorectal cancer (CRC) treatment (NCT04054908) coupled to cell culture and mouse experiments. Substantial shifts in gut microbial community structure during oral fluoropyrimidine treatment across multiple patient cohorts, in mouse small and large intestinal contents, and in patient-derived ex vivo communities were revealed by 16 S rRNA gene sequencing. Metagenomic sequencing revealed marked shifts in pyrimidine-related gene abundance during oral fluoropyrimidine treatment, including enrichment of the preTA operon, which was sufficient for the inactivation of active metabolite 5-fluorouracil (5-FU). preTA+ bacteria depleted 5-FU in gut microbiota grown ex vivo and in the mouse distal gut. Germ-free and antibiotic-treated mice experienced increased fluoropyrimidine toxicity, which was rescued by colonization with the mouse gut microbiota, preTA+Escherichia coli , or preTA -high stool from patients with CRC. Last, preTA abundance was negatively associated with fluoropyrimidine toxicity in patients. Together, these data support a causal, clinically relevant interaction between a human gut bacterial operon and the dose-limiting side effects of cancer treatment. Our approach may be generalizable to other drugs, including cancer immunotherapies, and provides valuable insights into host-microbiome interactions in the context of disease.
Purpose: Immune checkpoint inhibitors (ICI) have limited activity as monotherapy in biliary cancers. Granulocyte–macrophage colony-stimulating factor (GM-CSF) is a pleiotropic immune cell growth factor that achieved prolonged survival when combined with ipilimumab in melanoma. We conducted a single-center, phase II trial to evaluate the efficacy and safety of combining GM-CSF with pembrolizumab in patients with advanced biliary cancers after prior chemotherapy but no prior ICI. Patients and Methods: Pembrolizumab 200 mg was administered intravenously in 21-day cycles, along with two cycles of GM-CSF 250 μg subcutaneously on days 1 through 14. The primary endpoint was the objective response rate (ORR). Results: Among 42 patients enrolled, the median age was 61 years; 67% had intrahepatic cholangiocarcinoma, 90% had stage IV disease, and 24% had underlying viral hepatitis. The confirmed ORR was 12% (95% confidence interval, 4–26), including two patients with a complete response, and 26% of patients had progression-free survival (PFS) ongoing at 6 months. Treatment was well tolerated, with treatment-related grade 3 to 4 events in 7% and treatment-related serious adverse events in 10%. Tumor programmed cell death ligand 1 expression was present in 46% and was associated with a higher rate of 6-month PFS. Paired tumor biopsies showed upregulation of CD8+ T-cell populations and antigen processing pathways after the addition of GM-CSF. Conclusions: The addition of GM-CSF to pembrolizumab was well tolerated but did not meet the prespecified response rate for efficacy. A subset of patients experienced deep responses and prolonged stable disease. GM-CSF elicited changes in the tumor immune microenvironment that could guide future combination approaches.